China’s Landwind Diagnostics Maker Target Of Global Investors
This article was originally published in PharmAsia News
A pair of global equity firms are eyeing China's Landwind as a possible investment target. Citi Venture Capital International already owns about 70 percent of the maker and distributor of diagnostic-imaging equipment. But the U.S. equity firms are among about 20 private-equity firms, including many in China, considering making bids for Landwind. (Click here for more
You may also be interested in...
FDA's COVID-19 Naughty List Now Includes Marketers Of Copper Germ Stoppers, ‘24-Hour’ Hand Sanitizer
Warning letters issued by the US FDA on 28 May target two companies using COVID-19 and other disease-prevention claims to market purported germ-killing products, including a rub touted as 24-hour protection and a line of copper rollers and other implements to disinfect hands and personal items.
Industry-funded survey by Charles River Associates explores diverse perceptions about pricing for high-cost cell treatments – including curative cell and gene therapy – among various stakeholder groups.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.